Keith M. Gregg

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Juha O. Rinne, David J. Brooks, Martin N. Rossor et al. · The Lancet Neurology · 2010 · 695 citations

Life Sciences, Neurology, Neuroscience +17

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Reisa A. Sperling, Stephen Salloway, David J. Brooks et al. · The Lancet Neurology · 2012 · 510 citations

Medicine, Neurology, Neuroscience +12

Response Surface Model for Anesthetic Drug Interactions

Charles F. Minto, Thomas W. Schnider, Timothy G. Short et al. · Anesthesiology · 2000 · 355 citations · Full text

Medicine, Anesthesiology, Pharmacology +17

Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer-controlled infusion pump

Steven L. Shafer, Keith M. Gregg · Journal of Pharmacokinetics and Biopharmaceutics · 1992 · 256 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +16

Using the Time of Maximum Effect Site Concentration to Combine Pharmacokinetics and Pharmacodynamics

Charles F. Minto, Thomas W. Schnider, Keith M. Gregg et al. · Anesthesiology · 2003 · 161 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17